Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2019

Open Access 01-06-2019 | Metastasis

Cause and effect of microenvironmental acidosis on bone metastases

Authors: Sofia Avnet, Gemma Di Pompo, Silvia Lemma, Nicola Baldini

Published in: Cancer and Metastasis Reviews | Issue 1-2/2019

Login to get access

Abstract

Skeletal involvement is a frequent and troublesome complication in advanced cancers. In the process of tumor cells homing to the skeleton to form bone metastases (BM), different mechanisms allow tumor cells to interact with cells of the bone microenvironment and seed in the bone tissue. Among these, tumor acidosis has been directly associated with tumor invasion and aggressiveness in several types of cancer although it has been less explored in the context of BM. In bone, the association of local acidosis and cancer invasiveness is even more important for tumor expansion since the extracellular matrix is formed by both organic and hard inorganic matrices and bone cells are used to sense protons and adapt or react to a low pH to maintain tissue homeostasis. In the BM microenvironment, increased concentration of protons may derive not only from glycolytic tumor cells but also from tumor-induced osteoclasts, the bone-resorbing cells, and may influence the progression or symptoms of BM in many different ways, by directly enhancing cancer cell motility and aggressiveness, or by modulating the functions of bone cells versus a pro-tumorigenic phenotype, or by inducing bone pain. In this review, we will describe and discuss the cause of acidosis in BM, its role in BM microenvironment, and which are the final effectors that may be targeted to treat metastatic patients.
Literature
1.
2.
Mercadante, S. (1997). Malignant bone pain: pathophysiology and treatment. Pain, 69(1–2), 1–18.CrossRefPubMed
3.
Rucci, N., & Teti, A. (2018). Osteomimicry: how the seed grows in the soil. Calcified Tissue International, 102(2), 131–140.CrossRefPubMed
4.
Clezardin, P. (2017). Pathophysiology of bone metastases from solid malignancies. Joint, Bone, Spine, 84(6), 677–684.CrossRef
5.
6.
Compton, J. T., & Lee, F. Y. (2014). A review of osteocyte function and the emerging importance of sclerostin. The Journal of Bone and Joint Surgery. American Volume, 96(19), 1659–1668.CrossRefPubMedPubMedCentral
7.
Sottnik, J. L., Dai, J., Zhang, H., Campbell, B., & Keller, E. T. (2015). Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Research, 75(11), 2151–2158.CrossRefPubMedPubMedCentral
8.
Yoneda, T., Hiasa, M., & Okui, T. (2018). Crosstalk between sensory nerves and cancer in bone. Current Osteoporosis Reports, 16(6), 648–656.CrossRefPubMed
9.
10.
Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B., & Gillies, R. J. (2006). Acid-mediated tumor invasion: a multidisciplinary study. Cancer Research, 66(10), 5216–5223.CrossRefPubMed
11.
Kolosenko, I., Avnet, S., Baldini, N., Viklund, J., & De Milito, A. (2017). Therapeutic implications of tumor interstitial acidification. Seminars in Cancer Biology, 43, 119–133.CrossRefPubMed
12.
Corbet, C., & Feron, O. (2017). Tumour acidosis: from the passenger to the driver’s seat. Nature Reviews. Cancer, 17(10), 577–593.CrossRefPubMed
13.
Lloyd, M. C., Cunningham, J. J., Bui, M. M., Gillies, R. J., Brown, J. S., & Gatenby, R. A. (2016). Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces. Cancer Research, 76(11), 3136–3144.CrossRefPubMedPubMedCentral
14.
Mantyh, P. W., Clohisy, D. R., Koltzenburg, M., & Hunt, S. P. (2002). Molecular mechanisms of cancer pain. Nature Reviews. Cancer, 2(3), 201–209.CrossRefPubMed
15.
Kedika, R. R., Souza, R. F., & Spechler, S. J. (2009). Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Digestive Diseases and Sciences, 54(11), 2312–2317.CrossRefPubMedPubMedCentral
16.
Rousselle, A. V., & Heymann, D. (2002). Osteoclastic acidification pathways during bone resorption. Bone, 30(4), 533–540.CrossRefPubMed
17.
Avnet, S., Di Pompo, G., Lemma, S., Salerno, M., Perut, F., Bonuccelli, G., et al. (2013). V-ATPase is a candidate therapeutic target for Ewing sarcoma. Biochimica et Biophysica Acta, 1832(8), 1105–1116.CrossRefPubMed
18.
Martinez-Zaguilan, R., Martinez, G. M., Gomez, A., Hendrix, M. J., & Gillies, R. J. (1998). Distinct regulation of pHin and [Ca2+]in in human melanoma cells with different metastatic potential. Journal of Cellular Physiology, 176(1), 196–205.CrossRefPubMed
19.
Mazhab-Jafari, M. T., Rohou, A., Schmidt, C., Bueler, S. A., Benlekbir, S., Robinson, C. V., et al. (2016). Atomic model for the membrane-embedded VO motor of a eukaryotic V-ATPase. Nature, 539(7627), 118–122.CrossRefPubMedPubMedCentral
20.
Kane, P. M. (1995). Disassembly and reassembly of the yeast vacuolar H(+)-ATPase in vivo. The Journal of Biological Chemistry, 270(28), 17025–17032.PubMed
21.
Xu, T., Vasilyeva, E., & Forgac, M. (1999). Subunit interactions in the clathrin-coated vesicle vacuolar (H(+))-ATPase complex. The Journal of Biological Chemistry, 274(41), 28909–28915.CrossRefPubMed
22.
Sumner, J. P., Dow, J. A., Earley, F. G., Klein, U., Jager, D., & Wieczorek, H. (1995). Regulation of plasma membrane V-ATPase activity by dissociation of peripheral subunits. The Journal of Biological Chemistry, 270(10), 5649–5653.CrossRefPubMed
23.
Hinton, A., Sennoune, S. R., Bond, S., Fang, M., Reuveni, M., Sahagian, G. G., et al. (2009). Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. The Journal of Biological Chemistry, 284(24), 16400–16408.CrossRefPubMedPubMedCentral
24.
Toyomura, T., Oka, T., Yamaguchi, C., Wada, Y., & Futai, M. (2000). Three subunit a isoforms of mouse vacuolar H(+)-ATPase. Preferential expression of the a3 isoform during osteoclast differentiation. The Journal of Biological Chemistry, 275(12), 8760–8765.CrossRefPubMed
25.
Whitton, B., Okamoto, H., Packham, G., & Crabb, S. J. (2018). Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer. Cancer Medicine, 7(8), 3800–3811.CrossRefPubMedPubMedCentral
26.
Sennoune, S. R., Bakunts, K., Martinez, G. M., Chua-Tuan, J. L., Kebir, Y., Attaya, M. N., et al. (2004). Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. American Journal of Physiology. Cell Physiology, 286(6), C1443–C1452.CrossRefPubMed
27.
Nishisho, T., Hata, K., Nakanishi, M., Morita, Y., Sun-Wada, G. H., Wada, Y., et al. (2011). The a3 isoform vacuolar type H(+)-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Molecular Cancer Research, 9(7), 845–855.CrossRefPubMed
28.
Capecci, J., & Forgac, M. (2013). The function of vacuolar ATPase (V-ATPase) a subunit isoforms in invasiveness of MCF10a and MCF10CA1a human breast cancer cells. The Journal of Biological Chemistry, 288(45), 32731–32741.CrossRefPubMedPubMedCentral
29.
McConnell, M., Feng, S., Chen, W., Zhu, G., Shen, D., Ponnazhagan, S., et al. (2017). Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity. Oncotarget, 8(29), 47675–47690.CrossRefPubMedPubMedCentral
30.
Di Pompo, G., Lemma, S., Canti, L., Rucci, N., Ponzetti, M., Errani, C., et al. (2017). Intratumoral acidosis fosters cancer-induced bone pain through the activation of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinoma. Oncotarget, 8(33), 54478–54496.CrossRefPubMedPubMedCentral
31.
Kim, H. M., Jung, W. H., & Koo, J. S. (2014). Site-specific metabolic phenotypes in metastatic breast cancer. Journal of Translational Medicine, 12, 354.CrossRefPubMedPubMedCentral
32.
Lemma, S., Di Pompo, G., Porporato, P. E., Sboarina, M., Russell, S., Gillies, R. J., et al. (2017). MDA-MB-231 breast cancer cells fuel osteoclast metabolism and activity: a new rationale for the pathogenesis of osteolytic bone metastases. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1863(12), 3254–3264.CrossRefPubMed
33.
Song, I., Kim, J. H., Kim, K., Jin, H. M., Youn, B. U., & Kim, N. (2009). Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Letters, 583(14), 2435–2440.CrossRefPubMed
34.
Sreenivas, A., & Sastry, P. S. (1995). Purification and partial characterization of acyl carrier proteins from developing oil seeds of pisa (Actinodaphne hookeri) and ground nut (Arachis hypogaea). Indian Journal of Biochemistry & Biophysics, 32(3), 137–146.
35.
Massey, H. M., & Flanagan, A. M. (1999). Human osteoclasts derive from CD14-positive monocytes. British Journal of Haematology, 106(1), 167–170.CrossRefPubMed
36.
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003). Osteoclast differentiation and activation. Nature, 423(6937), 337–342.CrossRefPubMed
37.
Evangelisti, C., Bernasconi, P., Cavalcante, P., Cappelletti, C., D’Apice, M. R., Sbraccia, P., et al. (2015). Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. Oncotarget, 6(10), 7424–7437.CrossRefPubMedPubMedCentral
38.
Mulari, M. T., Zhao, H., Lakkakorpi, P. T., & Vaananen, H. K. (2003). Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptake. Traffic, 4(2), 113–125.CrossRefPubMed
39.
Baron, R., Neff, L., Louvard, D., & Courtoy, P. J. (1985). Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. The Journal of Cell Biology, 101(6), 2210–2222.CrossRefPubMed
40.
Silver, I. A., Murrills, R. J., & Etherington, D. J. (1988). Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Experimental Cell Research, 175(2), 266–276.CrossRefPubMed
41.
Blair, H. C., Teitelbaum, S. L., Ghiselli, R., & Gluck, S. (1989). Osteoclastic bone resorption by a polarized vacuolar proton pump. Science, 245(4920), 855–857.CrossRefPubMed
42.
Lee, B. S., Holliday, L. S., Ojikutu, B., Krits, I., & Gluck, S. L. (1996). Osteoclasts express the B2 isoform of vacuolar H(+)-ATPase intracellularly and on their plasma membranes. The American Journal of Physiology, 270(1 Pt 1), C382–C388.CrossRefPubMed
43.
Qin, A., Cheng, T. S., Pavlos, N. J., Lin, Z., Dai, K. R., & Zheng, M. H. (2012). V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. The International Journal of Biochemistry & Cell Biology, 44(9), 1422–1435.CrossRef
44.
45.
Kelly, M. E., Dixon, S. J., & Sims, S. M. (1994). Outwardly rectifying chloride current in rabbit osteoclasts is activated by hyposmotic stimulation. The Journal of Physiology, 475(3), 377–389.CrossRefPubMedPubMedCentral
46.
Lee, S. H., Kim, T., Park, E. S., Yang, S., Jeong, D., Choi, Y., et al. (2008). NHE10, an osteoclast-specific member of the Na+/H+ exchanger family, regulates osteoclast differentiation and survival [corrected]. Biochemical and Biophysical Research Communications, 369(2), 320–326.CrossRefPubMed
47.
Riihonen, R., Nielsen, S., Vaananen, H. K., Laitala-Leinonen, T., & Kwon, T. H. (2010). Degradation of hydroxyapatite in vivo and in vitro requires osteoclastic sodium-bicarbonate co-transporter NBCn1. Matrix Biology, 29(4), 287–294.CrossRefPubMed
48.
Wu, J., Glimcher, L. H., & Aliprantis, A. O. (2008). HCO3-/Cl- anion exchanger SLC4A2 is required for proper osteoclast differentiation and function. Proceedings of the National Academy of Sciences of the United States of America, 105(44), 16934–16939.CrossRefPubMedPubMedCentral
49.
Gupta, A., Edwards, J. C., & Hruska, K. A. (1996). Cellular distribution and regulation of NHE-1 isoform of the NA-H exchanger in the avian osteoclast. Bone, 18(2), 87–95.CrossRefPubMed
50.
Brisson, L., Reshkin, S. J., Gore, J., & Roger, S. (2012). pH regulators in invadosomal functioning: proton delivery for matrix tasting. European Journal of Cell Biology, 91(11–12), 847–860.CrossRefPubMed
51.
Lemma, S., Sboarina, M., Porporato, P. E., Zini, N., Sonveaux, P., Di Pompo, G., et al. (2016). Energy metabolism in osteoclast formation and activity. The International Journal of Biochemistry & Cell Biology, 79, 168–180.CrossRef
52.
Zecchin, A., Stapor, P. C., Goveia, J., & Carmeliet, P. (2015). Metabolic pathway compartmentalization: an underappreciated opportunity? Current Opinion in Biotechnology, 34, 73–81.CrossRefPubMed
53.
Iwamoto, T., Mamiya, N., Masushige, S., & Kida, S. (2005). PLCgamma2 activates CREB-dependent transcription in PC12 cells through phosphorylation of CREB at serine 133. Cytotechnology, 47(1–3), 107–116.CrossRefPubMedPubMedCentral
54.
Pollari, S., Kakonen, S. M., Edgren, H., Wolf, M., Kohonen, P., Sara, H., et al. (2011). Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Research and Treatment, 125(2), 421–430.CrossRefPubMed
55.
Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. J., et al. (2011). Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genetics, 43(9), 869–874.CrossRefPubMedPubMedCentral
56.
Khacho, M., Tarabay, M., Patten, D., Khacho, P., MacLaurin, J. G., Guadagno, J., et al. (2014). Acidosis overrides oxygen deprivation to maintain mitochondrial function and cell survival. Nature Communications, 5, 3550.CrossRefPubMed
57.
Mueller, S. C., & Chen, W. T. (1991). Cellular invasion into matrix beads: localization of beta 1 integrins and fibronectin to the invadopodia. Journal of Cell Science, 99(Pt 2), 213–225.PubMed
58.
Murphy, D. A., & Courtneidge, S. A. (2011). The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nature Reviews. Molecular Cell Biology, 12(7), 413–426.CrossRefPubMedPubMedCentral
59.
Destaing, O., Saltel, F., Geminard, J. C., Jurdic, P., & Bard, F. (2003). Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein. Molecular Biology of the Cell, 14(2), 407–416.CrossRefPubMedPubMedCentral
60.
Linder, S., Nelson, D., Weiss, M., & Aepfelbacher, M. (1999). Wiskott-Aldrich syndrome protein regulates podosomes in primary human macrophages. Proceedings of the National Academy of Sciences of the United States of America, 96(17), 9648–9653.CrossRefPubMedPubMedCentral
61.
Binks, M., Jones, G. E., Brickell, P. M., Kinnon, C., Katz, D. R., & Thrasher, A. J. (1998). Intrinsic dendritic cell abnormalities in Wiskott-Aldrich syndrome. European Journal of Immunology, 28(10), 3259–3267.CrossRefPubMed
62.
Moreau, V., Tatin, F., Varon, C., & Genot, E. (2003). Actin can reorganize into podosomes in aortic endothelial cells, a process controlled by Cdc42 and RhoA. Molecular and Cellular Biology, 23(19), 6809–6822.CrossRefPubMedPubMedCentral
63.
Burgstaller, G., & Gimona, M. (2005). Podosome-mediated matrix resorption and cell motility in vascular smooth muscle cells. American Journal of Physiology. Heart and Circulatory Physiology, 288(6), H3001–H3005.CrossRefPubMed
64.
Buccione, R., Orth, J. D., & McNiven, M. A. (2004). Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nature Reviews. Molecular Cell Biology, 5(8), 647–657.CrossRefPubMed
65.
Ayala, I., Baldassarre, M., Giacchetti, G., Caldieri, G., Tete, S., Luini, A., et al. (2008). Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. Journal of Cell Science, 121(Pt 3), 369–378.CrossRefPubMed
66.
Busco, G., Cardone, R. A., Greco, M. R., Bellizzi, A., Colella, M., Antelmi, E., et al. (2010). NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. The FASEB Journal, 24(10), 3903–3915.CrossRefPubMed
67.
Licon-Munoz, Y., Michel, V., Fordyce, C. A., & Parra, K. J. (2017). F-actin reorganization by V-ATPase inhibition in prostate cancer. Biology Open, 6(11), 1734–1744.CrossRefPubMedPubMedCentral
68.
Bourguignon, L. Y., Singleton, P. A., Diedrich, F., Stern, R., & Gilad, E. (2004). CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. The Journal of Biological Chemistry, 279(26), 26991–27007.CrossRefPubMed
69.
Oliferenko, S., Paiha, K., Harder, T., Gerke, V., Schwarzler, C., Schwarz, H., et al. (1999). Analysis of CD44-containing lipid rafts: recruitment of annexin II and stabilization by the actin cytoskeleton. The Journal of Cell Biology, 146(4), 843–854.CrossRefPubMedPubMedCentral
70.
Steffan, J. J., Snider, J. L., Skalli, O., Welbourne, T., & Cardelli, J. A. (2009). Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic, 10(6), 737–753.CrossRefPubMed
71.
Magalhaes, M. A., Larson, D. R., Mader, C. C., Bravo-Cordero, J. J., Gil-Henn, H., Oser, M., et al. (2011). Cortactin phosphorylation regulates cell invasion through a pH-dependent pathway. The Journal of Cell Biology, 195(5), 903–920.CrossRefPubMedPubMedCentral
72.
Cardone, R. A., Greco, M. R., Capulli, M., Weinman, E. J., Busco, G., Bellizzi, A., et al. (2012). NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. Molecular Biology of the Cell, 23(11), 2028–2040.CrossRefPubMedPubMedCentral
73.
Delaisse, J. M., Engsig, M. T., Everts, V., del Carmen Ovejero, M., Ferreras, M., Lund, L., et al. (2000). Proteinases in bone resorption: obvious and less obvious roles. Clinica Chimica Acta, 291(2), 223–234.CrossRef
74.
Vaananen, H. K., & Laitala-Leinonen, T. (2008). Osteoclast lineage and function. Archives of Biochemistry and Biophysics, 473(2), 132–138.CrossRefPubMed
75.
Lin, H. M., Nakamura, H., Noda, T., & Ozawa, H. (1994). Localization of H(+)-ATPase and carbonic anhydrase II in ameloblasts at maturation. Calcified Tissue International, 55(1), 38–45.CrossRefPubMed
76.
Toyomura, T., Murata, Y., Yamamoto, A., Oka, T., Sun-Wada, G. H., Wada, Y., et al. (2003). From lysosomes to the plasma membrane: localization of vacuolar-type H+ -ATPase with the a3 isoform during osteoclast differentiation. The Journal of Biological Chemistry, 278(24), 22023–22030.CrossRefPubMed
77.
Tomura, H., Wang, J. Q., Liu, J. P., Komachi, M., Damirin, A., Mogi, C., et al. (2008). Cyclooxygenase-2 expression and prostaglandin E2 production in response to acidic pH through OGR1 in a human osteoblastic cell line. Journal of Bone and Mineral Research, 23(7), 1129–1139.CrossRefPubMed
78.
Komarova, S. V., Pereverzev, A., Shum, J. W., Sims, S. M., & Dixon, S. J. (2005). Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Proceedings of the National Academy of Sciences of the United States of America, 102(7), 2643–2648.CrossRefPubMedPubMedCentral
79.
Pereverzev, A., Komarova, S. V., Korcok, J., Armstrong, S., Tremblay, G. B., Dixon, S. J., et al. (2008). Extracellular acidification enhances osteoclast survival through an NFAT-independent, protein kinase C-dependent pathway. Bone, 42(1), 150–161.CrossRefPubMed
80.
Okito, A., Nakahama, K., Akiyama, M., Ono, T., & Morita, I. (2015). Involvement of the G-protein-coupled receptor 4 in RANKL expression by osteoblasts in an acidic environment. Biochemical and Biophysical Research Communications, 458(2), 435–440.CrossRefPubMed
81.
Hikiji, H., Endo, D., Horie, K., Harayama, T., Akahoshi, N., Igarashi, H., et al. (2014). TDAG8 activation inhibits osteoclastic bone resorption. The FASEB Journal, 28(2), 871–879.CrossRefPubMed
82.
Jahr, H., van Driel, M., van Osch, G. J., Weinans, H., & van Leeuwen, J. P. (2005). Identification of acid-sensing ion channels in bone. Biochemical and Biophysical Research Communications, 337(1), 349–354.CrossRefPubMed
83.
Lieben, L., & Carmeliet, G. (2012). The involvement of TRP channels in bone homeostasis. Frontiers in Endocrinology (Lausanne), 3, 99.
84.
Kato, K., & Morita, I. (2013). Promotion of osteoclast differentiation and activation in spite of impeded osteoblast-lineage differentiation under acidosis: effects of acidosis on bone metabolism. Bioscience Trends, 7(1), 33–41.PubMed
85.
Idris, A. I., Landao-Bassonga, E., & Ralston, S. H. (2010). The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone, 46(4), 1089–1099.CrossRefPubMed
86.
Abed, E., Labelle, D., Martineau, C., Loghin, A., & Moreau, R. (2009). Expression of transient receptor potential (TRP) channels in human and murine osteoblast-like cells. Molecular Membrane Biology, 26(3), 146–158.CrossRefPubMed
87.
Tomura, H., Mogi, C., Sato, K., & Okajima, F. (2005). Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors. Cellular Signalling, 17(12), 1466–1476.CrossRefPubMed
88.
Ludwig, M. G., Vanek, M., Guerini, D., Gasser, J. A., Jones, C. E., Junker, U., et al. (2003). Proton-sensing G-protein-coupled receptors. Nature, 425(6953), 93–98.CrossRefPubMed
89.
Krishtal, O. (2003). The ASICs: signaling molecules? Modulators? Trends in Neurosciences, 26(9), 477–483.CrossRefPubMed
90.
Tominaga, M., & Tominaga, T. (2005). Structure and function of TRPV1. Pflügers Archiv, 451(1), 143–150.CrossRefPubMed
91.
Ishii, S., Kihara, Y., & Shimizu, T. (2005). Identification of T cell death-associated gene 8 (TDAG8) as a novel acid sensing G-protein-coupled receptor. The Journal of Biological Chemistry, 280(10), 9083–9087.CrossRefPubMed
92.
Murakami, N., Yokomizo, T., Okuno, T., & Shimizu, T. (2004). G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. The Journal of Biological Chemistry, 279(41), 42484–42491.CrossRefPubMed
93.
Frick, K. K., Krieger, N. S., Nehrke, K., & Bushinsky, D. A. (2009). Metabolic acidosis increases intracellular calcium in bone cells through activation of the proton receptor OGR1. Journal of Bone and Mineral Research, 24(2), 305–313.CrossRefPubMed
94.
Yang, M., Mailhot, G., Birnbaum, M. J., MacKay, C. A., Mason-Savas, A., & Odgren, P. R. (2006). Expression of and role for ovarian cancer G-protein-coupled receptor 1 (OGR1) during osteoclastogenesis. The Journal of Biological Chemistry, 281(33), 23598–23605.CrossRefPubMed
95.
Li, H., Wang, D., Singh, L. S., Berk, M., Tan, H., Zhao, Z., et al. (2009). Abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer G protein-coupled receptor 1. PLoS One, 4(5), e5705.CrossRefPubMedPubMedCentral
96.
Arnett, T. R. (2010). Acidosis, hypoxia and bone. Archives of Biochemistry and Biophysics, 503(1), 103–109.CrossRefPubMed
97.
Granchi, D., Torreggiani, E., Massa, A., Caudarella, R., Di Pompo, G., & Baldini, N. (2017). Potassium citrate prevents increased osteoclastogenesis resulting from acidic conditions: implication for the treatment of postmenopausal bone loss. PLoS One, 12(7), e0181230.CrossRefPubMedPubMedCentral
98.
Salamanna, F., Borsari, V., Contartese, D., Nicoli Aldini, N., & Fini, M. (2018). Link between estrogen deficiency osteoporosis and susceptibility to bone metastases: a way towards precision medicine in cancer patients. Breast, 41, 42–50.CrossRefPubMed
99.
Pagani, S., Fini, M., Giavaresi, G., Salamanna, F., & Borsari, V. (2015). The active role of osteoporosis in the interaction between osteoblasts and bone metastases. Bone, 79, 176–182.CrossRefPubMed
100.
Kato, K., & Morita, I. (2011). Acidosis environment promotes osteoclast formation by acting on the last phase of preosteoclast differentiation: a study to elucidate the action points of acidosis and search for putative target molecules. European Journal of Pharmacology, 663(1–3), 27–39.CrossRefPubMed
101.
Kato, K., & Matsushita, M. (2014). Proton concentrations can be a major contributor to the modification of osteoclast and osteoblast differentiation, working independently of extracellular bicarbonate ions. Journal of Bone and Mineral Metabolism, 32(1), 17–28.CrossRefPubMed
102.
Meghji, S., Morrison, M. S., Henderson, B., & Arnett, T. R. (2001). pH dependence of bone resorption: mouse calvarial osteoclasts are activated by acidosis. American Journal of Physiology. Endocrinology and Metabolism, 280(1), E112–E119.CrossRefPubMed
103.
Teti, A., Blair, H. C., Schlesinger, P., Grano, M., Zambonin-Zallone, A., Kahn, A. J., et al. (1989). Extracellular protons acidify osteoclasts, reduce cytosolic calcium, and promote expression of cell-matrix attachment structures. The Journal of Clinical Investigation, 84(3), 773–780.CrossRefPubMedPubMedCentral
104.
Arnett, T. R., & Spowage, M. (1996). Modulation of the resorptive activity of rat osteoclasts by small changes in extracellular pH near the physiological range. Bone, 18(3), 277–279.CrossRefPubMed
105.
Yuan, F. L., Xu, M. H., Li, X., Xinlong, H., Fang, W., & Dong, J. (2016). The roles of acidosis in osteoclast biology. Frontiers in Physiology, 7, 222.CrossRefPubMedPubMedCentral
106.
Biskobing, D. M., & Fan, D. (2000). Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature osteoclasts. Calcified Tissue International, 67(2), 178–183.CrossRefPubMed
107.
Nordstrom, T., Shrode, L. D., Rotstein, O. D., Romanek, R., Goto, T., Heersche, J. N., et al. (1997). Chronic extracellular acidosis induces plasmalemmal vacuolar type H+ ATPase activity in osteoclasts. The Journal of Biological Chemistry, 272(10), 6354–6360.CrossRefPubMed
108.
Miyazaki, T., Katagiri, H., Kanegae, Y., Takayanagi, H., Sawada, Y., Yamamoto, A., et al. (2000). Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. The Journal of Cell Biology, 148(2), 333–342.CrossRefPubMedPubMedCentral
109.
Frick, K. K., & Bushinsky, D. A. (2003). Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism. Journal of Bone and Mineral Research, 18(7), 1317–1325.CrossRefPubMed
110.
Frick, K. K., LaPlante, K., & Bushinsky, D. A. (2005). RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. American Journal of Physiology. Renal Physiology, 289(5), F1005–F1011.CrossRefPubMed
111.
Disthabanchong, S., Martin, K. J., McConkey, C. L., & Gonzalez, E. A. (2002). Metabolic acidosis up-regulates PTH/PTHrP receptors in UMR 106-01 osteoblast-like cells. Kidney International, 62(4), 1171–1177.CrossRefPubMed
112.
Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England Journal of Medicine, 315(26), 1650–1659.CrossRefPubMed
113.
Borriello, L., Nakata, R., Sheard, M. A., Fernandez, G. E., Sposto, R., Malvar, J., et al. (2017). Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells. Cancer Research, 77(18), 5142–5157.CrossRefPubMedPubMedCentral
114.
Kalluri, R. (2016). The biology and function of fibroblasts in cancer. Nature Reviews. Cancer, 16(9), 582–598.CrossRefPubMed
115.
Barcellos-de-Souza, P., Gori, V., Bambi, F., & Chiarugi, P. (2013). Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochimica et Biophysica Acta, 1836(2), 321–335.PubMed
116.
Chakkalakal, D. A., Mashoof, A. A., Novak, J., Strates, B. S., & McGuire, M. H. (1994). Mineralization and pH relationships in healing skeletal defects grafted with demineralized bone matrix. Journal of Biomedical Materials Research, 28(12), 1439–1443.CrossRefPubMed
117.
Massa, A., Perut, F., Chano, T., Woloszyk, A., Mitsiadis, T. A., Avnet, S., et al. (2017). The effect of extracellular acidosis on the behaviour of mesenchymal stem cells in vitro. European Cells & Materials, 33, 252–267.CrossRef
118.
Bischoff, D. S., Zhu, J. H., Makhijani, N. S., & Yamaguchi, D. T. (2008). Acidic pH stimulates the production of the angiogenic CXC chemokine, CXCL8 (interleukin-8), in human adult mesenchymal stem cells via the extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and NF-kappaB pathways. Journal of Cellular Biochemistry, 104(4), 1378–1392.CrossRefPubMed
119.
Peppicelli, S., Bianchini, F., Toti, A., Laurenzana, A., Fibbi, G., & Calorini, L. (2015). Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression. Cell Cycle, 14(19), 3088–3100.CrossRefPubMedPubMedCentral
120.
Crane, J. L., & Cao, X. (2014). Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. The Journal of Clinical Investigation, 124(2), 466–472.CrossRefPubMedPubMedCentral
121.
Sterling, J. A., Edwards, J. R., Martin, T. J., & Mundy, G. R. (2011). Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone, 48(1), 6–15.CrossRefPubMed
122.
Juarez, P., & Guise, T. A. (2011). TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone, 48(1), 23–29.CrossRefPubMed
123.
124.
Avnet, S., Di Pompo, G., Chano, T., Errani, C., Ibrahim-Hashim, A., Gillies, R. J., et al. (2017). Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-kappaB activation. International Journal of Cancer, 140(6), 1331–1345.CrossRefPubMedPubMedCentral
125.
Karin, M., & Greten, F. R. (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nature Reviews. Immunology, 5(10), 749–759.CrossRefPubMed
126.
Sims, N. A. (2016). Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption. The International Journal of Biochemistry & Cell Biology, 79, 14–23.CrossRef
127.
Coleman, R. E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research, 12(20 Pt 2), 6243s–6249s.CrossRefPubMed
128.
Delaney, A., Fleetwood-Walker, S. M., Colvin, L. A., & Fallon, M. (2008). Translational medicine: cancer pain mechanisms and management. British Journal of Anaesthesia, 101(1), 87–94.CrossRefPubMed
129.
Yoneda, T., Hiasa, M., Nagata, Y., Okui, T., & White, F. A. (2015). Acidic microenvironment and bone pain in cancer-colonized bone. Bonekey Report, 4, 690.CrossRef
130.
Mach, D. B., Rogers, S. D., Sabino, M. C., Luger, N. M., Schwei, M. J., Pomonis, J. D., et al. (2002). Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience, 113(1), 155–166.CrossRefPubMed
131.
Julius, D., & Basbaum, A. I. (2001). Molecular mechanisms of nociception. Nature, 413(6852), 203–210.CrossRefPubMed
132.
133.
Tessier-Lavigne, M., & Placzek, M. (1991). Target attraction: are developing axons guided by chemotropism? Trends in Neurosciences, 14(7), 303–310.CrossRefPubMed
134.
Li, Y., Jia, Y. C., Cui, K., Li, N., Zheng, Z. Y., Wang, Y. Z., et al. (2005). Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. Nature, 434(7035), 894–898.CrossRefPubMed
135.
Simmons, J. K., Hildreth, B. E., 3rd, Supsavhad, W., Elshafae, S. M., Hassan, B. B., Dirksen, W. P., et al. (2015). Animal models of bone metastasis. Veterinary Pathology, 52(5), 827–841.CrossRefPubMedPubMedCentral
136.
Slosky, L. M., Largent-Milnes, T. M., & Vanderah, T. W. (2015). Use of animal models in understanding cancer-induced bone pain. Cancer Growth Metastasis, 8(Suppl 1), 47–62.PubMedPubMedCentral
137.
Robey, I. F., Baggett, B. K., Kirkpatrick, N. D., Roe, D. J., Dosescu, J., Sloane, B. F., et al. (2009). Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Research, 69(6), 2260–2268.CrossRefPubMedPubMedCentral
138.
Ibrahim-Hashim, A., Wojtkowiak, J. W., de Lourdes Coelho Ribeiro, M., Estrella, V., Bailey, K. M., Cornnell, H. H., et al. (2011). Free base lysine increases survival and reduces metastasis in prostate cancer model. Journal of Cancer Science and Therapy, Suppl 1(4).
139.
Silva, A. S., Yunes, J. A., Gillies, R. J., & Gatenby, R. A. (2009). The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Research, 69(6), 2677–2684.CrossRefPubMedPubMedCentral
140.
Gillies, R. J., Pilot, C., Marunaka, Y., & Fais, S. (2019). Targeting acidity in cancer and diabetes. Biochimica et Biophysica Acta, Reviews on Cancer, 1871(2), 273–280.CrossRefPubMed
141.
Huss, M., & Wieczorek, H. (2009). Inhibitors of V-ATPases: old and new players. The Journal of Experimental Biology, 212(Pt 3), 341–346.CrossRefPubMed
142.
Mattsson, J. P., Vaananen, K., Wallmark, B., & Lorentzon, P. (1991). Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochimica et Biophysica Acta, 1065(2), 261–268.CrossRefPubMed
143.
Marchetti, P., Milano, A., D’Antonio, C., Romiti, A., Falcone, R., Roberto, M., et al. (2016). Association between proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumors: a randomized phase II trial. Clinical Colorectal Cancer, 15(4), 377–380.CrossRefPubMed
144.
Wang, B. Y., Zhang, J., Wang, J. L., Sun, S., Wang, Z. H., Wang, L. P., et al. (2015). Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. Journal of Experimental & Clinical Cancer Research, 34, 85.CrossRef
145.
Spugnini, E. P., Buglioni, S., Carocci, F., Francesco, M., Vincenzi, B., Fanciulli, M., et al. (2014). High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. Journal of Translational Medicine, 12, 225.CrossRefPubMedPubMedCentral
146.
Hiasa, M., Okui, T., Allette, Y. M., Ripsch, M. S., Sun-Wada, G. H., Wakabayashi, H., et al. (2017). Bone pain induced by multiple myeloma is reduced by targeting V-ATPase and ASIC3. Cancer Research, 77(6), 1283–1295.CrossRefPubMedPubMedCentral
147.
Nagae, M., Hiraga, T., Wakabayashi, H., Wang, L., Iwata, K., & Yoneda, T. (2006). Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone, 39(5), 1107–1115.CrossRefPubMed
148.
Izumi, M., Ikeuchi, M., Ji, Q., & Tani, T. (2012). Local ASIC3 modulates pain and disease progression in a rat model of osteoarthritis. Journal of Biomedical Science, 19, 77.CrossRefPubMedPubMedCentral
149.
Karczewski, J., Spencer, R. H., Garsky, V. M., Liang, A., Leitl, M. D., Cato, M. J., et al. (2010). Reversal of acid-induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2. British Journal of Pharmacology, 161(4), 950–960.CrossRefPubMedPubMedCentral
150.
Ghilardi, J. R., Rohrich, H., Lindsay, T. H., Sevcik, M. A., Schwei, M. J., Kubota, K., et al. (2005). Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. The Journal of Neuroscience, 25(12), 3126–3131.CrossRefPubMedPubMedCentral
151.
Fuseya, S., Yamamoto, K., Minemura, H., Yamaori, S., Kawamata, T., & Kawamata, M. (2016). Systemic QX-314 reduces bone cancer pain through selective inhibition of transient receptor potential vanilloid subfamily 1-expressing primary afferents in mice. Anesthesiology, 125(1), 204–218.CrossRefPubMed
152.
Niiyama, Y., Kawamata, T., Yamamoto, J., Furuse, S., & Namiki, A. (2009). SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. British Journal of Anaesthesia, 102(2), 251–258.CrossRefPubMed
153.
Supuran, C. T., & Winum, J. Y. (2015). Carbonic anhydrase IX inhibitors in cancer therapy: an update. Future Medicinal Chemistry, 7(11), 1407–1414.CrossRefPubMed
154.
Pastorek, J., & Pastorekova, S. (2015). Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Seminars in Cancer Biology, 31, 52–64.CrossRefPubMed
155.
Supuran, C. T. (2018). Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opinion on Investigational Drugs, 27(12), 963–970.CrossRefPubMed
156.
Tauro, M., Loiodice, F., Ceruso, M., Supuran, C. T., & Tortorella, P. (2014). Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors. Bioorganic & Medicinal Chemistry Letters, 24(12), 2617–2620.CrossRef
157.
Zhang, X., Lin, Y., & Gillies, R. J. (2010). Tumor pH and its measurement. Journal of Nuclear Medicine, 51(8), 1167–1170.CrossRefPubMed
Metadata
Title
Cause and effect of microenvironmental acidosis on bone metastases
Authors
Sofia Avnet
Gemma Di Pompo
Silvia Lemma
Nicola Baldini
Publication date
01-06-2019
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2019
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-019-09790-9

Other articles of this Issue 1-2/2019

Cancer and Metastasis Reviews 1-2/2019 Go to the issue

ReviewPaper

Pro- and antitumor effects of mitochondrial reactive oxygen species

Correction

Correction to: Tumor pH and metastasis: a malignant process beyond hypoxia

Clinical

Multiple treatment lines and prognosis in metastatic colorectal cancer patients

ReviewPaper

Acidosis and cancer: from mechanism to neutralization

ReviewPaper

Intracellular pH dynamics and charge-changing somatic mutations in cancer

NON-THEMATIC REVIEW

Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits